Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
8 Jan 24
8-K
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
5 Dec 23
8-K
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
8 Nov 23
8-K
Termination of a Material Definitive Agreement
5 Oct 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
8-K
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
28 Sep 23
8-K
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
27 Sep 23
8-K
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
21 Aug 23
8-K
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
15 Aug 23
Registration and prospectus
S-3ASR
Automatic shelf registration
8 Nov 23
D
$30.00 mm in equity, sold $30.00 mm, 2 investors
16 Oct 23
S-8
Registration of securities for employees
13 Jun 23
424B5
Prospectus supplement for primary offering
7 Nov 22
S-8
Registration of securities for employees
10 Jun 22
S-3ASR
Automatic shelf registration
24 Feb 22
S-3ASR
Automatic shelf registration
9 Nov 21
D
$199.92M in equity / options, sold $199.92M, 9 investors
13 Oct 21
S-8
Registration of securities for employees
22 Jun 21
S-3ASR
Automatic shelf registration
2 Feb 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Sep 21
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
8 May 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
Other
CT ORDER
Confidential treatment order
18 Mar 19
CT ORDER
Confidential treatment order
23 Oct 18
CT ORDER
Confidential treatment order
19 Aug 16
CT ORDER
Confidential treatment order
22 Mar 16
CORRESP
Correspondence with SEC
4 May 15
EFFECT
Notice of effectiveness
4 May 15
CORRESP
Correspondence with SEC
1 May 15
UPLOAD
Letter from SEC
12 Mar 15
CT ORDER
Confidential treatment order
31 Mar 14
EFFECT
Notice of effectiveness
12 Feb 14
Ownership
4
Bradley L Campbell
19 Mar 24
4/A
Bradley L Campbell
15 Mar 24
4/A
John F Crowley
15 Mar 24
4/A
David Michael Clark
15 Mar 24
4/A
Jeff Castelli
15 Mar 24
4/A
Ellen Rosenberg
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
GLENN SBLENDORIO
11 Mar 24
4
MICHAEL RAAB
6 Mar 24
4
MARGARET G MCGLYNN
6 Mar 24